Corcept Therapeutics Incorporated
CORT
$69.57
$0.751.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 23.67% | -13.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.67% | -13.57% | |||
| Cost of Revenue | 42.86% | -18.71% | |||
| Gross Profit | 23.37% | -13.48% | |||
| SG&A Expenses | 14.55% | 8.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.07% | -1.81% | |||
| Operating Income | 680.88% | -86.48% | |||
| Income Before Tax | 229.51% | -69.91% | |||
| Income Tax Expenses | 68.37% | -1,000.25% | |||
| Earnings from Continuing Operations | 71.07% | -33.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 71.07% | -33.17% | |||
| EBIT | 680.88% | -86.48% | |||
| EBITDA | 628.48% | -85.51% | |||
| EPS Basic | 70.55% | -33.53% | |||
| Normalized Basic EPS | 229.81% | -70.06% | |||
| EPS Diluted | 70.59% | -33.41% | |||
| Normalized Diluted EPS | 227.49% | -70.23% | |||
| Average Basic Shares Outstanding | 0.00% | 0.45% | |||
| Average Diluted Shares Outstanding | 0.56% | 1.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||